- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Repligen Corporation(RGEN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RGEN
11/19/2026: RGEN (2-star) is currently NOT-A-BUY. Pass it for now.
Repligen Corporation is a mid-cap life sciences tools company that specializes in bioprocessing consumables and systems for biological drug manufacturing. The company benefits from strong gross margins, proprietary filtration and chromatography technologies, and recurring revenue streams from consumable product lines. Its primary growth driver centers on capturing demand in advanced modalities like gene therapy, reinforced by strategic expansions such as the BioLife Solutions integration. However, the business faces risks related to customer inventory cycles, elevated valuation multiples, and the execution challenge of resolving internal financial control weaknesses. The stock best suits growth-oriented investors willing to navigate cyclical biopharma spending trends while monitoring order book recovery and integration milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | Repligen targets expansion in high-growth bioprocessing and cell therapy segments. |
| Momentum investor | Strong fit while signal remains positive | The stock experiences notable price momentum during periods of biopharmaceutical industry order recovery. |
| Value investor | Mixed fit | Valuation multiples often remain elevated relative to traditional industrial or healthcare peers due to long-term growth expectations. |
| Dividend investor | Weak fit | The company does not pay dividends, prioritizing capital reinvestment and M&A. |
| Low-risk investor | Weak fit | Earnings volatility and cyclical industry exposure create notable equity price fluctuations. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock is sensitive to shifts in biopharmaceutical capital expenditure cycles and sector sentiment. |
| Valuation risk | High | Pricing often reflects optimistic long-term growth assumptions, leaving little room for execution missteps. |
| Competition risk (large conglomerate competition) | Medium / high | Well-capitalized life science giants can bundle competing bioprocessing products. |
| Business quality | Strong | Repligen features high gross margins and strong technological positioning in core niche workflows. |
| Dividend income | Low / none | Income-focused investors receive no cash return via dividends. |
| Execution risk | Medium / high | Integrating large acquisitions like BioLife Solutions while resolving internal financial control weaknesses demands careful management. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.04B USD | Price to earnings Ratio - | 1Y Target Price 203.21 |
Price to earnings Ratio - | 1Y Target Price 203.21 | ||
Volume (30-day avg) 1.2M shares | Beta 1.12 | 52 Weeks Range 100.99 - 198.87 | Updated Date 11/19/2026 |
52 Weeks Range 100.99 - 198.87 | Updated Date 11/19/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.21 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 61.0%
- Active BUY / eligible
- 64 / 105
- 30-Day BUY Count Change
- +16
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Instruments & Supplies
- BUY participation
- 40.0%
- Active BUY / eligible
- 2 / 5
- 30-Day BUY Count Change
- 0
Eligible universe: 5 stocks.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 0.22% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Filtration Products | Single-use and reusable hollow-fiber and flat-sheet filtration modules used in upstream and downstream processing. | This is the company's largest revenue pillar, driven by recurring customer demand for consumable filtration items. |
| Chromatography Products | OPUS pre-packed columns and systems designed to streamline biomolecule separation. | Provides efficient purification solutions that save drug developers significant time in manufacturing setup. |
| Proteins Products | Affinity ligands and specialized resins used for high-purity biological drug isolation. | Offers high-margin, proprietary inputs integral to monoclonal antibody and gene therapy manufacturing. |
| Process Analytics | Real-time sensing and desktop analytical instruments (PAT). | Helps clients monitor production quality and optimize yields during active drug manufacturing batches. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-10-27 | When Before Market | Estimate 0.46 | Actual 0.53 |
Profitability
Profit Margin -1.47% | Operating Margin (TTM) 8.14% |
Management Effectiveness
Return on Assets (TTM) 1.4% | Return on Equity (TTM) -0.57% |
Valuation
Trailing PE - | Forward PE 58.48 | Enterprise Value 10.19B | Price to Sales(TTM) 13.7 |
Enterprise Value 10.19B | Price to Sales(TTM) 13.7 | ||
Enterprise Value to Revenue 12.65 | Enterprise Value to EBITDA 80 | Shares Outstanding 63.92M | Shares Floating 60.96M |
Shares Outstanding 63.92M | Shares Floating 60.96M | ||
Percent Insiders 4.87 | Percent Institutions 112.64 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

